1Pharma Division, Preclinical CNS Research, F. Hoffmann-La Roche, PRPN, 72/141, CH-4070, Basel, Switzerland. jean-luc.moreau@roche.com
Central adenosine A(2A) receptors are key in brain function and disease. Targeting these receptors with antagonists or agonists may offer new treatments for neurodegenerative disorders, seizures, and sleep conditions.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: